The tweet was deleted by the author.
But we saved everything 🙂.
NeoGenomics has announced a preview of its booth activities for the upcoming USCAP2026 event, encouraging attendees to visit booth 639 for a firsthand experience of its latest pathology and oncology diagnostics solutions.
The company has opened meeting bookings for event participants, highlighting its ongoing engagement within the clinical pathology and oncology space. Further details about their offerings are expected to be revealed during the conference. Details are being clarified.
NeoGenomics' expanding portfolio of diagnostics aligns with broader trends the company has pursued, including advancements in spatial biology to address challenges such as immunotherapy resistance, as explored in recent research showcased at the NextGen Omics Spatial and Data U.S. 2026 event. These initiatives build upon innovations like the introduction of PanTracer Pro, aimed at streamlining molecular testing and improving clinical outcomes, underscoring NeoGenomics’ commitment to shaping the future of oncology diagnostics.